Clinical Protocol and Data Management
Clinical Protocol and Data Management
批准号:
9975833
负责人:
JONATHAN C TRENT
金额:
$20.93万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AddressAgeBone Marrow TransplantationCancer Center Support GrantCancer PatientCatchment AreaChildClinicalClinical DataClinical ManagementClinical ProtocolsClinical ResearchClinical TrialsComprehensive Cancer CenterDataDevelopmentEducationEnrollmentEnsureEthicsEthnic OriginFloridaFundingGenderGuidelinesHispanicsIndividualIndustryInfrastructureInstitutional PolicyInterventionIntervention StudiesLanguageLocationMalignant Childhood NeoplasmMalignant NeoplasmsMinorityMonitorNational Clinical Trials NetworkNursing ResearchOperations ResearchPatientsPediatric Oncology GroupPeer ReviewPoliciesProcessProtocols documentationQuality ControlRaceRegulationRegulatory AffairsReportingResearchResearch InfrastructureResearch PersonnelRiskSafetyServicesSystemTimeTrainingTranslational ResearchUnited States National Institutes of HealthUniversitiesWomanWritinganticancer researchbasedata managementmemberoperationpatient safetyquality assuranceracial minorityrecruitresearch studysexual identity
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY: CLINICAL PROTOCOL AND DATA MANAGEMENT
Part I: Clinical Protocol and Data Management (CPDM). The Sylvester Comprehensive Cancer Center
(Sylvester) Clinical Research Services (CRS) provides Clinical Protocol and Data Management (CPDM)
support for the conduct of cancer-related research studies at Sylvester, including the Downtown Miami
Campus and four satellite locations. CRS comprises three units: 1) The Clinical Trials Coordination Unit
(CTCU); 2) Research Committee Support Unit (RCSU); and 3) Quality Assurance Unit (QAU). The purpose of
CRS is to provide a centralized, high quality infrastructure to support investigators with developing,
implementing, and reporting on all Sylvester cancer research studies, with the safety of participating subjects
as the highest priority. CRS assists with the activation and completion of clinical studies, accurately reports
clinical study data, and ensures consistency and quality for all studies. The CTCU is comprised of Operations
(Research Nurse support, data management, and study coordination) and Regulatory Affairs (regulatory
support for timely initiation, compliance, and all protocol review and approval processes). The RCSU facilitates
the administration of research committees. including the Protocol Review and Monitoring Committee and Data
and Safety Monitoring Committee. The QAU ensures patient safety by providing quality assurance and training
for CRS staff and monitoring compliance with Sylvester’s Data and Safety Monitoring Plan (DSMP) and all
applicable policy and regulations. CRS supports National Clinical Trials Network, NCI-funded, peer-reviewed,
investigator-initiated, and industry-sponsored studies. CRS uses the clinical trial management system Velos
eResearch for patient and protocol registration and tracking requirements. In CY 2017, Sylvester CRS
supported 1,518 interventional, 509 interventional treatment, and 3,050 non-interventional accruals.
Part II: Data and Safety Monitoring (DSM). Sylvester’s DSMC performs risk-based monitoring to ensure the
highest levels of patient safety for all Sylvester investigator-initiated studies. CRS provides effective quality
control and education to Sylvester investigators and research staff to ensure compliance with the Sylvester
DSMP.
Part III: Inclusion of Women and Minorities. Sylvester has initiated and sustained many proactive efforts to
promote recruitment of women and minorities into research. In CY 2017, enrollment to interventional studies
comprised 45% women, 52% Hispanic, and 22% racial minorities, including Blacks and other individuals who
self-identify as non-white.
Part IV: Inclusion of Children. Sylvester supports the NIH policy and guidelines on the inclusion of children in
research. As a member of the Children’s Oncology Group (COG) and the COG Pediatric Bone Marrow
Transplant Consortium, Sylvester maintains a comprehensive clinical study portfolio for all pediatric cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical Protocol and Data Management
-
批准号:10190868
-
项目类别:
-
资助金额:$21.55万
-
财政年份:2019
-
负责人:JONATHAN C TRENT
-
依托单位:
Protocol Review and Monitoring System
-
批准号:10443650
-
项目类别:
-
资助金额:$3.93万
-
财政年份:2019
-
负责人:JONATHAN C TRENT
-
依托单位:
Protocol Review and Monitoring System
-
批准号:9789593
-
项目类别:
-
资助金额:$3.6万
-
财政年份:2019
-
负责人:JONATHAN C TRENT
-
依托单位:
Protocol Review and Monitoring System
-
批准号:10670859
-
项目类别:
-
资助金额:$4.05万
-
财政年份:2019
-
负责人:JONATHAN C TRENT
-
依托单位:
Protocol Review and Monitoring System
-
批准号:10190869
-
项目类别:
-
资助金额:$3.81万
-
财政年份:2019
-
负责人:JONATHAN C TRENT
-
依托单位:
Clinical Protocol and Data Management
-
批准号:10443648
-
项目类别:
-
资助金额:$22.2万
-
财政年份:2019
-
负责人:JONATHAN C TRENT
-
依托单位:
Clinical Protocol and Data Management
-
批准号:9789592
-
项目类别:
-
资助金额:$20.32万
-
财政年份:2019
-
负责人:JONATHAN C TRENT
-
依托单位:
Clinical Protocol and Data Management
-
批准号:10670858
-
项目类别:
-
资助金额:$22.87万
-
财政年份:2019
-
负责人:JONATHAN C TRENT
-
依托单位:
CHAPERONIN (SULFOLOBUS SHIBATAE)
-
批准号:7953782
-
项目类别:
-
资助金额:$1.74万
-
财政年份:2008
-
负责人:JONATHAN C TRENT
-
依托单位:
CHAPERONIN (SULFOLOBUS SHIBATAE)
-
批准号:7721150
-
项目类别:
-
资助金额:$1.62万
-
财政年份:2007
-
负责人:JONATHAN C TRENT
-
依托单位:
CHAPERONIN (SULFOLOBUS SHIBATAE)
-
批准号:7598624
-
项目类别:
-
资助金额:$0.81万
-
财政年份:2006
-
负责人:JONATHAN C TRENT
-
依托单位:
CHAPERONIN (SULFOLOBUS SHIBATAE)
-
批准号:7357816
-
项目类别:
-
资助金额:$0.75万
-
财政年份:2005
-
负责人:JONATHAN C TRENT
-
依托单位:
CHAPERONINS AS SELF-ASSEMBLING BUILDING BLOCKS FOR NANOTECHNOLOGY
-
批准号:7183094
-
项目类别:
-
资助金额:$1.31万
-
财政年份:2005
-
负责人:JONATHAN C TRENT
-
依托单位:
Activity & resistance of Gleevec in GI stromal tumors
-
批准号:6812235
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2004
-
负责人:JONATHAN C TRENT
-
依托单位:
Mechanism/activity/resistance/Gleevec/GI stromal tumors (K23M)
-
批准号:7082185
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2004
-
负责人:JONATHAN C TRENT
-
依托单位:
Activity & resistance of Gleevec in GI stromal tumors
-
批准号:7478111
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2004
-
负责人:JONATHAN C TRENT
-
依托单位:
Mechanism/activity/resistance/Gleevec/GI stromal tumors (K23M)
-
批准号:6918662
-
项目类别:
-
资助金额:$13.61万
-
财政年份:2004
-
负责人:JONATHAN C TRENT
-
依托单位:
CHARACTERIZE STRUCT OF MOLECULAR CHAPERONES CYTOSTRUCTURE OF PROKARYOTIC CELL
-
批准号:6117283
-
项目类别:
-
资助金额:$1.13万
-
财政年份:1998
-
负责人:JONATHAN C TRENT
-
依托单位:
CHARACTERIZE STRUCT OF MOLECULAR CHAPERONES CYTOSTRUCTURE OF PROKARYOTIC CELL
-
批准号:6278478
-
项目类别:
-
资助金额:$1.6万
-
财政年份:1998
-
负责人:JONATHAN C TRENT
-
依托单位:
CHAPERONIN FILAMENTS ARCHAEAL CYTOSTRUCTURE
-
批准号:6280699
-
项目类别:
-
资助金额:$0.27万
-
财政年份:1998
-
负责人:JONATHAN C TRENT
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: